Alprostadil is under clinical development by Seelos Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Alprostadil’s likelihood of approval (LoA) and phase transition for Raynauds Disease took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Alprostadil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Alprostadil overview

Alprostadil (Vitaros, Virirec, Vytaros) is a potent vasodilator agent. It is formulated in the form of cream for topical application. It is indicated in the treatment of men ≥ 18 years of age with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Alprostadil is under development for the treatment of Rayva for Raynaud’s phenomenon secondary to scleroderma.The drug candidate was also under development for the treatment of wounds and female hypoactive sexual desire disorder.

Seelos Therapeutics overview

Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.

Quick View Alprostadil LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Alprostadil
Administration Pathway
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Male Health
  • Women’s Health
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.